POSTDOCTORAL RESEARCHERS - JUAN DE LA CIERVA-FORMACIÓN
Deadline for application
We are looking for ambitious, creative, and scientifically curious researchers who meet the Juan de la Cierva-Formación eligibility criteria set by the call:
- Be in the possession of a doctoral degree at the call deadline
- Thesis defense date must be in the period between the January 1st, 2020 and December 31st, 2021
- Mobility rule: predoctoral training not at IJC.
- At the call deadline, researchers may not:
- have applied to Ramon y Cajal 2021 call
- be beneficiary of previous calls of Juan de la Cierva, Formación Postdoctoral, Juan de la Cierva-Formación or Juan de la Cierva-Incorporación.
Enjoying a Juan de la Cierva-Formación fellowship at IJC will allow you to gain research experience, develop research maturity, improve your professional skills and make grow your international profile and network.
The Josep Carreras Leukemia Research Institute (IJC) is a non-profit research institute based in Barcelona and dedicated to advancing our understanding about leukemia and related disorders, in partnership with the University of Barcelona and University Autònoma of Barcelona. The IJC has laboratories in three clinical campuses: i) Clinic Hospital, ii) Sant Pau Hospital and iii) Germans Trias i Pujol Hospital. IJC serves as a collaborative hub for basic investigators and physicians to work together on fundamental biological and clinical aspects of leukemia. The IJC offers an excellent work environment built around a multi-disciplinary fusion of ideas and state-of-the-art facilities.
The European Commission awarded the IJC the HR Excellence seal in July 2019. The IJC continues to work to maintain its policies in line with the Charter and Code principles.
The HRS4R has the main objective of ensuring that research centers of excellence implement and respect the requirements of the European Charter for Researchers and the Code of Conduct for hiring researchers (from here on referred to as the Charter and Code) within their human resources policies.
This EC initiative aims to promote training, professional development, and mobility for all European scientists. The IJC supports these values and principles, which will not only serve to strengthen its internal policies but will actively stimulate excellent research and firmly situate the organization as an institution with a stimulating working environment that favors the development of its scientists.
IJC is an equal opportunity employer. We evaluate qualified applicants without regard to race, color, religion, sex, national origin, disability, and other legally protected characteristics.
We welcome applications from researchers eager to study biocomputational, translational and clinical epigenetics data and to foster interactions with Oncologists, Hematologists, and Pathologists at Dr. Esteller’s Cancer Epigenetics Group.
Dr. Manel Esteller, Director at Josep Carreras Leukaemia Research Institute (IJC) and principal investigator of the Cancer Epigenetics Group, is involved in the analysis of the type and mechanisms of epigenetic and epitranscriptomics alterations in cancer cells, including aberrant changes in DNA methylation, histone and RNA modifications in cancer, the study of the epigenetics/epitranscriptomics machinery and associated mutations, and finally, testing of epigenetic/epitranscriptomics drugs.
Information regarding the Group Leader, composition of the research team, lines of research of the group and competitive funding can be found here: https://www.carrerasresearch.org/en/cancer-epigenetics_124284
Place of presentation of the candidacies
How to apply?
The application will be done through an online application platform. If you are ready to take the next step in your research career, please apply to the Dr. Esteller’s call for Expressions of Interest.
Your Expression of Interest should be sent to firstname.lastname@example.org and include:
- Your CV including a full list of your publications, research grants and projects.
- Motivation letter.
- Copy of your PhD title
Deadline Expression of Interest
Please submit your application by January 28th, 2022.